Skip to main content
Cancers logoLink to Cancers
. 2023 Mar 29;15(7):2031. doi: 10.3390/cancers15072031

Breast, Prostate, Colorectal, and Lung Cancer Incidence and Risk Factors in Women Who Have Sex with Women and Men Who Have Sex with Men: A Cross-Sectional and Longitudinal Analysis Using UK Biobank

Sarah Underwood 1, Georgios Lyratzopoulos 2, Catherine L Saunders 1,*
Editor: Anne-Marie Bouvier
PMCID: PMC10093616  PMID: 37046692

Abstract

Simple Summary

In this analysis, we look at the number of new breast, lung, colorectal and prostate cancer diagnoses among women who have sex with women and men who have sex with men. In order to do this, we used data from UK Biobank, which is a research database that contains in-depth health information from approximately half a million people in the UK. We found no differences in the number of new cases for breast, prostate and colorectal cancer, but we did find that sexual minority adults have a higher risk for lung cancer, due to greater exposure to smoking.

Abstract

Background. There is limited evidence about cancer incidence for lesbian, gay and bisexual women and men, although the prevalence of cancer risk factors may be higher. Aim. To describe cancer incidence for four common cancers (breast, lung, colorectal and prostate). Methods. This project used UK Biobank participant data. We explored risk factor prevalence (age, deprivation, ethnicity, smoking, alcohol intake, obesity, parity, and sexual history), and calculated cancer risk, for six groups defined based on sexual history; women who have sex exclusively with men (WSEM), or women (WSEW), women who have sex with men and women (WSWM); men who have sex exclusively with women (MSEW), or men (MSEM), and men who have sex with women and men (MSWM). Results. WSEW, WSWM, MSEM, and MSMW were younger, more likely to smoke, and to live in more deprived neighbourhoods. We found no evidence of an association between sexual history and breast, colorectal, or prostate cancer in age-adjusted models. Lung cancer incidence was higher for WSWM compared with WSEM, HR (95%CI) 1.78 (1.28–2.48), p = 0.0005, and MSWM compared with MSEW, 1.43 (1.03–1.99), p = 0.031; after adjustment for smoking, this difference was no longer significant. Conclusions. Sexual minority groups have a higher risk for lung cancer, due to greater exposure to smoking.

Keywords: cancer epidemiology, cancer risk, cancer incidence, inequalities, sexual minority health

1. Introduction

There is limited evidence about cancer and other health outcomes for lesbian, gay and bisexual (LGB) people in the UK [1]. What research there is suggests poorer outcomes than for people who are heterosexual [2,3,4]. Much LGB health research to date has had a focus on sexually transmitted infections (STI), especially HIV/AIDs, and evidence on health and health care outcomes for long-term conditions including cancer is still emerging.

Working with the public when developing research improves both the quality and relevance of work, particularly when it relates to minority groups [5,6]. It enables a focus on issues important to the lives of patients and allows patients to offer their relevant insights of specific health conditions or of belonging to a specific group. For this project, during 2020–2022, we worked with an LGBTQ+ research involvement group to identify research priorities. The group identified cancer, and particularly lung, breast, and prostate cancer, as cancers they were interested in, or concerned about [7,8,9]. Along with colorectal cancer, these are the four commonest cancer diagnoses in the UK. The group also highlighted higher rates of smoking among sexual minority adults, and its link to cancer, as a key area of concern. Smoking is an important risk factor for cancer [10], and rates of smoking are higher amongst sexual minority groups, particularly LGB women [11,12].

Regarding cancer outcomes, cross-sectional studies exploring overall cancer prevalence among LGB adults found variation by sex, with higher cancer prevalence among gay men [13,14], and site-specific cancer research has highlighted disparities for rarer cancers that are causally linked to HIV [15,16] and human papilloma virus transmission (HPV), e.g., cervical, anal, and oropharyngeal cancer [16,17,18], rather than cancer diagnoses with most frequent incidence.

Poorer health and cancer outcomes experienced by LGB adults have multifactorial causes, both structural and individual [19]. LGB adults are more likely to live in areas of higher socio-economic deprivation [2]. Minority stress [20], where social prejudices, stigma, and discrimination contribute to an environment where health is adversely impacted is a second important dimension. Higher levels of risk factors for common cancers, developed in part through the complex interplay with minority stress, including obesity, smoking and high alcohol intake [21], are a third dimension. Parity, an important protective factor for breast cancer [22], is lower in sexual minority women [23].

Disparities in access to and quality of health care offered to sexual minority adults compared with their heterosexual counterparts are another contributor [2,24,25].

Although data, particularly cross-sectional survey data collections, are improving, and the UK National Cancer Registration and Analysis Service added sexual orientation to its core demographic dataset in 2018, this field is not yet mandatory, and longitudinal studies with an adequate sample size and collection of sexual identity as well as health and cancer outcome data are rare [26,27,28,29].

UK Biobank is a longitudinal cohort study which, between 2006 and 2010, collected rich information about cancer risk factors, and about sexual history, from 500,000 40–69 year olds [30]. Consent for data linkage was also collected and cancer diagnoses are linked from national cancer registration data, making this a valuable resource for understanding cancer risk among older sexual minority adults.

In order to address the lack of data on cancer outcomes from LGB adults, and building on patient and public identified priorities, as well as an understanding of known disparities in risk factors, this analysis used UK Biobank to answer the specific research question, ‘Are there differences in breast, lung, colorectal and prostate cancer incidence between sexual minority and heterosexual patients, and are such differences attributable to known risk factors?’.

2. Materials and Methods

2.1. Data

We evaluated cancer incidence among women who have sex with women and men who have sex with men using data from UK Biobank. At the time of recruitment to UK Biobank, participants were resident within 25 miles of 1 of 22 assessment centres in England (89% of participants), Scotland (7%), or Wales (4%) [31]. Data on a range of lifestyle factors were collected through a touch-screen questionnaire at baseline, and on cancer outcomes through linkage to national cancer registries. Full information on the study have been reported elsewhere [31,32]. The data used for this study were accessed through UK Biobank (application ID 42861).

2.2. Cancer

Using linked cancer registry data [33], breast cancer cases were defined with an ICD10 code of C50 or an ICD9 code of 1740, 1750, 1741, 1742, 1743, 1744, 1745, 1746, 1748, 1749, or 1759. Prostate cancer was defined with an ICD10 code of C61 or an ICD9 code of 185. Colon cancer was defined with an ICD10 code of C18 or an ICD9 code of 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, or 1539 and rectal cancer with ICD10 codes of C19 or C20, or an ICD9 code of 1540 or 1541; for analysis, these two cancers were combined to consider all colorectal cancer together. Lung cancer was defined by an ICD10 diagnosis code of C33 or C34 or an ICD9 code of 1620, 1622, 1623, 1624, 1625, 1628, or 1629. Both prevalent and incident cases were identified. Prevalent cases of all cancers were defined as any diagnosis with a cancer-registry-recorded date of diagnosis that occurred before the date of baseline assessment for the UK Biobank cohort (study entry), and people with prevalent cancer were excluded in the analysis of incident cancer (first recorded cancer diagnosis after study entry) on a cancer-by-cancer basis.

2.3. Sexual History

Sexual identity (whether someone identifies as lesbian, gay, or bisexual) overlaps with an individual’s sexual history [34]; at baseline assessment, UK Biobank only collected information about sexual history, and not on any other measure of sexual orientation. In previous work, we evaluated the use of sexual history for understanding health inequalities experienced by sexual minority women and men, and found that the measure, although not perfect, was adequate [30].

In detail, during the baseline touch-screen questionnaire, participants answered questions about their same and opposite-sex sexual history and were given the option to not answer these questions if they found them too sensitive. Participants were asked their total number of sexual partners, ‘About how many sexual partners have you had in your lifetime?’ and about their history of same-sex sex, ‘Have you ever had sexual intercourse with someone of the same sex?’ Participants indicating a history of same-sex sex were asked their number of same-sex sexual partners, ‘How many sexual partners of the same sex have you had in your lifetime?’ These responses were used to identify women and men who had never had sex, women who have sex exclusively with men (WSEM), or women (WSEW), women who have sex with men and women (WSWM); men who have sex exclusively with women (MSEW), or men (MSEM), and men who have sex with women and men (MSWM) (details in Appendix A). Women and men who had never had sex, or with missing responses to sexual history question were excluded from all analyses.

2.4. Cancer Risk Factors

The following known socio-demographic and health-related cancer risk factors were considered; age at baseline assessment, sex, smoking, alcohol consumption, ethnicity, deprivation, body mass index (BMI), parity in women, lifetime number of sexual partners and age at first intercourse.

This analysis used the ‘sex’ field rather than ‘genetic’ sex to classify participants as women or men. The sex field is acquired from central registry at recruitment, but in some cases updated by the participant. [35] Ethnicity was categorised based on five groups defined by the UK Office of National Statistics, and deprivation from the Townsend score for each participant, a small area-based measure of socio-economic deprivation, categorised using national quintile-defining cut-off points.

Smoking status was derived from responses to two questions ‘Do you smoke tobacco now?’, with responses ‘Yes, on most or all days’, ‘Only occasionally’, ‘No’ and ‘Prefer not to answer’; and ‘In the past, how often have you smoked tobacco?’, with responses ‘Smoked on most or all days’, ‘Smoked occasionally’, ‘Just tried once or twice’, ‘I have never smoked’ and ‘Prefer not to answer’. Informative responses were used to classify participants as ‘Current’, ‘Previous’, or ‘Never’ smokers.

Participants were asked about alcohol consumption, ‘About how often do you drink alcohol?’: ‘Daily or almost daily’, ‘Three or four times a week’, ‘Once or twice a week’, ‘One to three times a month’, ‘Special occasions only’, ‘Never’ and ‘Prefer not to answer’. ‘One to three times a month’ and ‘Special occasions only’ responses were combined in this analysis.

Continuous BMI was calculated using nurse-measured height and weight, then categorised with descriptors according to the WHO guidelines: <20 (underweight or lower healthy weight, aggregated because of low numbers), 20–24.9 (healthy weight), 25–29.9 (overweight), and 30+ (obese) [36].

Women were asked ‘How many children have you given birth to?’ and ‘Have you ever had any stillbirths, spontaneous miscarriages or terminations?’. Parity was calculated as the number of live-born children plus number of stillbirths and categorised into the following groups: parity 0; parity 1; parity 2; and parity 3+. Age of first sexual intercourse and the lifetime number of sexual partners were recorded from the initial sexual history measures.

2.5. Analysis

2.5.1. Descriptive Statistics

In our first analysis, we described cancer risk factor prevalence stratified by sex and sexual history for all participants where sexual history could be defined. Missing data for each cancer risk factor were excluded on a risk factor-by-risk factor basis.

2.5.2. Cancer Incidence

Prevalent cancer cases (on a cancer-by-cancer basis) and individuals with missing cancer risk factor data for any risk factor (except age of first intercourse, which was considered only in sensitivity analysis because of the high amount of missing data) were excluded for all unadjusted and adjusted analyses of cancer incidence.

Unadjusted breast, lung, colorectal and prostate cancer incidence were estimated stratified by sex and sexual history.

Person-time at risk for cancer incidence was calculated as time (in years) between baseline assessment, and the earliest of, the date of first site-specific incident cancer diagnosis (cases), date of death, or the date of last cancer registry linkage (censoring). The date of last cancer registry linkage is 29 February 2020 in England and Wales, and 31 January 2021 in Scotland, and we used the earlier date of 29 February 2020 in this analysis.

2.5.3. Multivariable Analysis

For each cancer, we used Cox regression and considered three models, unadjusted, adjusted for age, and fully adjusted for all significant cancer risk factors to explore the relationship between sexual history and common cancer incidence in UK Biobank for each cancer diagnosis, stratified by sex. The fully adjusted model, separately for women and men, for each diagnosis, was developed using a backward Akaike Information Criteria (AIC) stepwise function. Beginning with a ‘maximum’ model including all potential covariates (age, ethnicity, smoking, alcohol, parity, deprivation, BMI, and lifetime number of sexual partners), the AIC function simplifies the model by removing variables that do not significantly improve the model fit. The function was not permitted to exclude the sexual history variable regardless of its effect on model fit. All covariates were included as categorical variables in the multivariable analysis, except for age, where we included it as a continuous measure (with quadratic terms where this improved model fit).

2.5.4. Sensitivity Analyses

We explored the impact of missing data on these analyses in a series of sensitivity analyses.

All analyses were carried out using R version 4.2.1.

3. Results

3.1. Descriptive Statistics

After excluding respondents with missing sexual history, 403,637 UK Biobank participants were included in descriptive analysis including 214,801 WSEM, 700 WSEW and 5161 WSWM, 176,591 MSEW, 2111 MSEM, and 4273 MSWM. Analyses of cancer incidence were carried out on the smaller sample of 397,681 responses for whom complete covariate information was available (210,464 WSEM, 5048 WSWM, 688 WSEW, 175,162 MSEW, 2090 MSWM, 4229 MSEM), details Appendix A Figure A1.

MSEW and WSEM are generally older than other groups with the median (IQR) age in WSEM 57 (50–63), WSEW 50 (45–58), WSWM 51 (45–57), MSEW 58 (50–63), MSEM 51 (45–60), and MSWM 53 (47–61), and live in less deprived areas, with the median deprivation quintile in the study cohort the second least deprived for WSEM, WSEW and MSEW, the middle group for WSWM and MSEM, and the second most deprived for MSWM (Table 1, full details of counts in each group in Appendix B, Table A1). Men and women with a history of both same and opposite-sex sex are more likely to report daily or almost daily alcohol intake than those with a history of only same or opposite-sex sex, and to be current or previous smokers. WSEW (16.7%) and WSWM (21.1%) are much more likely be current or previous smokers than WSEM (11.5%), with similar patterns among men. WSEW (68.4%) and WSWM (43.4%) are much more likely than WSEM (15.6%) to have never had children.

Table 1.

Cohort characteristics, stratified by sexual history (%).

Women Who Have Sex Exclusively with Men (n = 214,801) Women Who Have Sex Exclusively with Women (n = 700) Women Who Have Sex with Women and Men (n = 5161) Men who Have Sex Exclusively with Women (n = 176,591) Men Who Have Sex Exclusively with Men (n = 2111) Men Who Have Sex with Women and Men (n = 4273)
Age (n = 403,637)
35–44 10.3 22.4 21.9 10.6 21.6 16.6
45–49 13.6 25.9 23.7 12.9 21.5 18.1
50–54 16.0 17.7 20.6 14.7 16.9 17.6
55–59 18.9 13.4 16.5 17.8 14.1 17.2
60–64 24.3 13.0 12.6 24.3 14.7 18.1
65+ 16.9 7.57 4.71 19.8 11.3 12.3
Ethnicity (n = 402,166)
White 96.0 91.7 95.1 96.0 94.2 93.2
Mixed 0.48 1.15 1.52 0.33 0.76 1.18
Asian 1.18 2.58 0.49 1.75 2.05 2.57
Black 1.33 1.72 1.76 1.05 0.95 1.41
Other/Chinese 1.00 2.87 1.17 0.82 2.05 1.65
Deprivation (n = 403,127)
Least Deprived 38.9 26.5 21.3 39.7 16.5 21.2
2 21.4 20.2 16.0 21.2 12.5 16.6
3 14.8 16.5 18.0 14.5 15.2 13.6
4 12.9 15.3 20.6 12.5 20.9 20.5
Most Deprived 12.0 21.6 24.1 12.1 34.9 28.1
Smoking (n = 402,633)
Current 8.29 14.6 19.2 11.5 16.7 21.1
Previous 31.1 30.8 43.7 38.8 31.3 40.7
Never 60.6 54.6 37.2 49.6 51.9 38.2
Alcohol (n = 403,480)
Daily or almost daily 16.5 16.9 23.3 26.3 26.9 30.6
3 or 4 times a week 21.4 19.4 22.9 27.1 22.5 22.2
1 or 2 times a week 26.1 24.4 23.4 25.7 23.0 22.4
1 to 3 times a month 27.5 27.0 23.9 15.5 20.7 17.4
Never 8.43 12.3 6.53 5.39 6.87 7.31
BMI (n = 403,637)
Under 20 3.32 2.86 3.89 0.89 2.37 1.47
20–25 36.6 33.6 37.7 24.2 33.1 27.7
25–30 36.6 36.3 34.1 49.6 42.2 45.8
30+ 23.5 27.3 24.3 25.4 22.4 25.0
Lifetime Sexual Partners (n = 403,637)
1 33.8 25.9 0.775 24.5 9.52 1.40
2 to 3 26.2 25.4 12.6 22.0 11.7 11.3
4 to 5 16.7 19.6 15.4 15.8 10.8 13.8
6+ 23.2 29.1 71.2 37.7 67.9 73.5
Age of First Intercourse (n = 396,622)
<15 2.51 3.42 10.2 4.92 11.9 15.1
15–17 31.3 24.1 41.9 30.0 20.0 32.3
18+ 66.2 72.5 47.9 65.1 68.2 52.6
Parity (n = 400,745)
0 15.6 68.4 43.4 100 100 100
1 12.9 5.19 15.5 0 0 0
2 45.4 16.9 26.9 0 0 0
3+ 26.1 9.52 14.2 0 0 0

3.2. Unadjusted Incidence

The number of incident cases and incidence rates are summarised in Table 2 and Table 3. Median length of follow up in all groups was 11 years (IQR 10–12). Breast cancer incidence in all women was higher than lung or colorectal, and in men prostate cancer incidence was highest. Cancer incidence for all diagnoses was highest in WSEM and MSEW, reflecting the older age profile of these groups (Table 1).

Table 2.

Incident cancer case numbers, and incidence rates in women, stratified by sexual history.

Cases Overall Cancer Incidence in UKBB per 1000 Person-Years Follow up
Breast
Women who have sex exclusively with men 6921 3.10 (3.03–3.17)
Women who have sex with women and men 158 2.92 (2.48–3.41)
Women who have sex exclusively with women 14 1.91 (1.04–3.20)
Lung
Women who have sex exclusively with men 1444 0.616 (0.585–0.649)
Women who have sex with women and men 38 0.676 (0.478–0.928)
Women who have sex exclusively with women 6 0.790 (0.290–1.72)
Colorectal
Women who have sex exclusively with men 1892 0.811 (0.775–0.849)
Women who have sex with women and men 34 0.606 (0.291–1.73)
Women who have sex exclusively with women 6 0.794 (0.420–0.846

Table 3.

Incident cancer case numbers, and incidence rates in men, stratified by sexual history.

Cases Overall Cancer Incidence in UKBB per 1000 Person-Years Follow up
Prostate
Men who have sex exclusively with women 8142 4.42 (4.33–4.52)
Men who have sex with women and men 166 3.74 (3.19–4.35)
Men who have sex exclusively with men 72 3.28 (2.57–4.13)
Lung
Men who have sex exclusively with women 1423 0.748 (0.709–0.788)
Men who have sex with women and men 39 0.855 (0.609–1.17)
Men who have sex exclusively with men 15 0.664 (0.372–1.10)
Colorectal
Men who have sex exclusively with women 2427 1.29 (1.24–1.34)
Men who have sex with women and men 50 1.10 (0.819–1.45)
Men who have sex exclusively with men 21 0.936 (0.580–1.43)

3.3. Multivariable Analysis

3.3.1. Women

There was no evidence of an association between sexual history and breast cancer risk (p > 0.08 in all models); although the incidence for WSEW breast cancer was lower in all models, this was not significant (Table 4).

Table 4.

Models of breast, lung, and colorectal cancer in women.

Unadjusted Age Adjusted * Full Model **
Hazard Ratio
(95% CI)
Hazard Ratio
(95% CI)
Hazard Ratio
(95% CI)
Breast Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSWM 0.91 (0.77–1.07) 1.01 (0.86–1.19) 0.93 (0.79–1.10)
WSEW 0.63 (0.37–1.06) 0.70 (0.41–1.18) 0.63 (0.37–1.07)
Joint p-value 0.087 0.35 0.13
Lung Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSWM 1.09 (0.79–1.51) 1.77 (1.28–2.46) 1.15 (0.82–1.59)
WSEW 1.30 (0.59–2.91) 2.06 (0.92–4.60) 1.56 (0.70–3.48)
Joint p-value 0.73 0.0022 0.44
Colorectal Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSWM 0.75 (0.53–1.06) 1.06 (0.75–1.50) 1.10 (0.78–1.56)
WSEW 1.01 (0.45–2.24) 1.40 (0.63–3.12) 1.37 (0.61–3.06)
Joint p-value 0.23 0.70 0.67

* Breast and lung cancer models adjusted with linear and quadratic age term. Colorectal cancer model adjusted with linear age term only. ** Full breast cancer model adjusted for age at recruitment (linear and quadratic terms), ethnicity, smoking, alcohol, parity, BMI. Lung cancer model adjusted for age at recruitment (linear and quadratic terms), Townsend category, smoking, alcohol, and BMI. Colorectal cancer model adjusted for age at recruitment (linear term only), smoking, lifetime number of sexual partners, BMI.

In an analysis adjusting only for age, we found higher lung cancer incidence among women with a history of both same and opposite-sex sex (p = 0.0022) HR (95%CI) 1.77 (1.28–2.46) and women with a history of same-sex sex only 2.06 (0.92–4.60). This was explained by a higher cancer smoking prevalence in fully adjusted models (Table 4 and Appendix C, Table A2). There was no evidence of an association between sexual history and incident colorectal cancer risk (p > 0.2 in all models).

3.3.2. Men

After accounting for differences in age, we found no evidence of an association between prostate, lung or colorectal cancer incidence with sexual history (Table 5). For MSWM, there was evidence 1.42 (1.02–1.97), p = 0.031 (stratum-specific p-value), that lung cancer incidence was higher than for MSEW, which disappeared after adjusting for smoking history (Table 4, Appendix C). Adjusting for cancer risk factors had a large impact on the size of the estimates for lung cancer; and for MSWM, this explained the higher cancer incidence seen in this group. Although prostate cancer rates are lower among men who have sex with men, this is explained by the lower age of this group.

Table 5.

Models of prostate, lung, and colorectal cancer in men.

Unadjusted Age Adjusted * Full Model **
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Prostate Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 0.84 (0.72–0.98) 1.07 (0.92–1.25) 1.10 (0.94–1.28)
MSEM 0.75 (0.59–0.94) 1.09 (0.86–1.37) 1.10 (0.87–1.39)
Joint p-value 0.0027 0.54 0.39
Lung Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 1.10 (0.79–1.52) 1.42 (1.02–1.97) 0.90 (0.64–1.25)
MSEM 0.90 (0.54–1.49) 1.31 (0.79–2.18) 1.03 (0.62–1.71)
Joint p-value 0.79 0.087 0.79
Colorectal Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 0.85 (0.64–1.13) 1.05 (0.79–1.40) 1.03 (0.77–1.36)
MSEM 0.74 (0.48–1.14) 1.01 (0.66–1.56) 1.05 (0.68–1.61)
Joint p-value 0.18 0.94 0.96

* Prostate, lung, and colorectal cancer models adjusted with linear and quadratic age term. ** Full prostate cancer model adjusted for age at recruitment (linear and quadratic term), ethnicity, smoking, alcohol, and BMI. Lung cancer model adjusted for age at recruitment (linear and quadratic term), Townsend category, smoking, lifetime number of sexual partners, alcohol, and BMI. Colorectal cancer model adjusted for age at recruitment (linear term and quadratic term), ethnicity, smoking, alcohol, and BMI.

Results were consistent in sensitivity analyses exploring the impact of missing data (Appendix D and Appendix E, Table A3, Table A4, Table A5 and Table A6).

4. Discussion

We explored cancer incidence for four common cancers among women who have sex with women and men who have sex with men using UK Biobank with linked cancer incidence data from national (UK) cancer registries. We found no evidence of an association between sexual history and breast, colorectal, or prostate cancer incidence in age-adjusted models. Lung cancer incidence was higher for WSWM compared with WSEM, and MSWM compared with MSEW; accounting for differences in smoking prevalence in these groups explained this higher incidence.

This study builds on existing knowledge about the higher prevalence of cancer risk factors, particularly smoking, among lesbian, gay and particularly bisexual adults [28,37,38,39,40,41], and adds new evidence about how these known disparities translate to poorer health outcomes.

Of the common cancer diagnoses we considered—lung, colorectal, breast, and prostate—we found disparities in age-adjusted incidence only for lung cancer. This provides additional evidence which builds on our earlier study which found that for most common and rarer cancer sites (except for those associated with HPV or HIV), the odds of specific cancer site diagnosis seemed to be independent of sexual orientation [16]. The novel finding here for lung cancer probably reflects that this analysis includes controls without cancer, rather than a case-only framework used in earlier work, which may have underestimated disparities associated with smoking as all study participants had a cancer diagnosis. However, it is not surprising that of all the cancers considered it is lung cancer where disparities in cancer risk factors among sexual minority women and men translate into poorer health outcomes. Of all common cancers, lung cancer is the one with the largest attributable fraction due to known lifestyle and environmental risk factors (chiefly smoking) [42,43].

Previous systematic reviews have highlighted the lack of high-quality data, and the importance of prospective cohort studies in producing evidence to better understanding breast cancer risk in lesbian and bisexual women [44] This study goes part of the way towards addressing this evidential need. Although we find no evidence of an association between sexual history and breast cancer incidence at this time, we do note that the sample size of included WSEW and WSWM was relatively small; further analysis as the UK Biobank cohort continues to be followed up over time may be warranted.

Despite our finding of no evidence of disparities in prostate cancer incidence for MSM, we do note that previous research has found that quality of life and some outcomes after prostate cancer treatment are poorer in this group; future research could explore whether lifestyle differences identified in this analysis have impact on cancer outcomes beyond cancer incidence considered in this research [45].

This research has important implications for both health policymakers and in clinical practice. In clinical practice, there is evidence that lesbian, gay and bisexual adults have poorer experiences of cancer care [25]; the evidence from this work that lesbian, gay and bisexual women and men are likely to be over-represented among people with lung cancer highlights the importance of work to improve holistic cancer care for LGB communities [46]. From a public health practice, and policy perspective, our work highlights that approaches to support smoking cessation among LGB communities will be particularly important and have the potential to make material differences to the inequalities in health outcomes experienced by sexual minority adults. It is also important to highlight that the higher prevalence of smoking among LGB adults arises from a complex interplay of minority stress and experiences of stigma and discrimination [19], and the historic targeting of LGBT communities by tobacco companies [47]; smoking cessation support is a practical area for redressing these inequalities.

There are limitations to this analysis; we describe inequalities experienced by women who have sex with women, and men who have sex with men, and sexual orientation was not recorded directly; previous research has found this is a reasonable approach [30], but future data collections should consider additionally including sexual orientation (and gender identity) as a priority. Having said this, it is important to acknowledge that sexual orientation alone is not inherently a risk factor for cancer, instead it is a proxy measure for the impact of experiencing chronic, toxic stress as well as health diminishing coping behaviours used to manage the negative experiences caused by heterosexism, and multi-level discrimination, stigma, and marginalisation.

Additionally we focus only on the four commonest cancers; disparities may exist for other cancers, for example, liver and oesophageal cancers, which are associated with alcohol consumption, which we find in this analysis, consistent with previous research [28], to be at higher levels among women who have sex with women and men who have sex with men.

In an earlier analysis, we explored the characteristics of UK Biobank participants with missing information about sexual history [30]. People with missing sexual history were older, and less likely to live in the least deprived parts of the UK, compared with women and men who have an exclusively opposite-sex sexual history. Although it is a limitation that approximately 20% of UK Biobank participants with missing sexual history were excluded in these analyses, we did adjust for both age and deprivation in multivariable analysis, mitigating this impact on the study findings. We were not able to explore disparities in cancer outcomes for trans and gender-diverse adults, and this is a further limitation. A strength of this research, however, is that it built on strong patient and public involvement [7,8,9], which is important to ensure that there is not a mismatch between research and the priorities of the communities it is designed to support [48].

5. Conclusions

Women who have sex with women and men who have sex with men are higher-risk groups for lung cancer due to greater exposure to smoking.

Acknowledgments

This research has been conducted using the UK Biobank Resource under Application Number 42861. This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (MC_PC_20029).

Appendix A

Figure A1.

Figure A1

Flowchart of analysis exclusions.

Appendix B. Cohort Characteristics, Stratified by Sexual History

Table A1.

Cohort characteristics, stratified by sexual history (counts for percentages presented in Table 1).

WSEM (n = 214801) WSEW (n = 700) WSWM (n = 5161) MSEW (n = 176591) MSEM (n = 2111) MSWM (n = 4273)
Age (n = 403,637)
35–44 22,036 157 1130 18,666 455 711
45–49 29,248 181 1223 22,720 453 775
50–54 34,412 124 1064 25,894 356 753
55–59 40,493 94 849 31,497 298 735
60–64 52,221 91 652 42,849 310 774
65+ 36,391 53 243 34,965 239 525
Ethnicity (n = 402,166)
White 205,569 639 4873 168,931 1980 3954
Mixed 1032 8 78 575 16 50
Asian 2519 18 25 3083 43 109
Black 2845 12 90 1853 20 60
Other/Chinese 2145 20 60 1446 43 70
Townsend Category (n = 403,127)
Least Deprived 83,399 185 1097 69,954 347 904
2 45,980 141 824 37,388 264 708
3 31,755 115 929 25,492 321 581
4 27,595 107 1062 22,107 440 876
Most Deprived 25,813 151 1241 21,414 735 1202
Alcohol (n = 403,480)
Daily or almost daily 35,556 118 1200 46,352 568 1307
3 or 4 times a week 45,941 136 1181 47,900 475 949
1 or 2 times a week 56,115 171 1206 45,426 486 955
1 to 3 times a month 59,007 189 1233 27,340 436 744
Never 18,100 86 337 9509 145 312
Smoking (n = 402,633)
Current 17,773 102 987 20,338 352 901
Previous 66,666 215 2248 68,411 660 1735
Never 129,826 382 1915 87,399 1092 1631
BMI (n = 403,637)
Under 20 7126 20 201 1566 50 63
20–25 78608 235 1948 42,703 699 1183
25–30 78596 254 1760 87,554 890 1958
30+ 50471 191 1252 44,768 472 1069
Lifetime Sexual Partners (n = 403,637)
1 72575 181 40 43,327 201 60
2 to 3 56385 178 649 38,833 248 482
4 to 5 35935 137 795 27,887 228 589
6+ 49906 204 3677 66,544 1434 3142
Age of First Intercourse (n = 396,622)
<15 5297 22 522 8524 244 641
15–17 66,085 155 2139 51,980 411 1368
18+ 139,812 466 2447 112,878 1402 2229
Parity (n = 400,745)
0 33,091 474 2216 176,591 2111 4273
1 27,254 36 789 0 0 0
2 96,245 117 1372 0 0 0
3+ 55,384 66 726 0 0 0

Appendix C

Table A2.

Model of lung cancer incidence in women and men. Adjusted only for age and smoking.

Hazard Ratio (95% CI)
Women
WSEM 1 (reference)
WSWM 0.845 (0.724–0.987)
WSEW 0.748 (0.591–0.947)
Joint p-value 0.31
Men
MSEW 1 (reference)
MSWM 1.104 (0.796–1.530)
MSEM 0.921 (0.554–1.533)
Joint p-value 0.63

Appendix D. The Analysis Was Undertaken without the Exclusion of the Age of First Intercourse Variable. Models Are Summarised in Table A3 (Women) and Table A4 (Men)

Table A3.

Models of breast, lung, and colorectal cancer in women.

Unadjusted Age Adjusted Full Model
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Breast Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSWM 0.91 (0.78–1.07) 1.01 (0.86–1.19) 0.93 (0.79–1.10)
WSEW 0.63 (0.37–1.09) 0.70 (0.41–1.20) 0.64 (0.37–1.10)
Joint p-value 0.11 0.39 0.16
Lung Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSWM 1.10 (0.79–1.53) 1.78 (1.29–2.48) 1.15 (0.82–1.59)
WSEW 1.42 (0.64–3.16) 2.19 (0.98–4.89) 1.76 (0.79–3.92)
Joint p-value 0.62 0.0016 0.34
Colorectal Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSEM 0.73 (0.52–1.04) 1.04 (0.73–1.48) 1.08 (0.75–1.54)
WSWM 1.09 (0.49–2.43) 1.50 (0.67–3.34) 1.47 (0.66–3.27)
Joint p-value 0.18 0.64 0.63

Table A4.

Models of prostate, lung, and colorectal cancer in men.

Unadjusted Age Adjusted Full Model
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Prostate Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 0.85 (0.72–0.99) 1.08 (0.93–1.27) 1.11 (0.95–1.29)
MSEM 0.75 (0.59–0.95) 1.09 (0.86–1.38) 1.10 (0.87–1.39)
Joint p-value 0.0040 0.48 0.33
Lung Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 1.10 (0.80–1.53) 1.43 (1.03–1.99) 0.89 (0.64–1.24)
MSEM 0.92 (0.55–1.53) 1.35 (0.81–2.24) 1.06 (0.64–1.77)
Joint p-value 0.80 0.072 0.76
Colorectal Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSWM 0.86 (0.65–1.14) 1.063 (0.801–1.411) 1.04 (0.78–1.38)
MSEM 0.65 (0.41–1.03) 0.89 (0.56–1.42) 0.92 (0.58–1.47)
Joint p-value 0.084 0.81 0.91

Appendix E. Due to the Issues with Low Sample Size, Especially for MSEM and WSEW, the Analysis Was Undertaken with the Variable of Interest Changed to ‘Ever Had Same-Sex Sex’. WSEM Were Compared with WSW and MSEM Were Compared with MSM. Models Are Summarised in Table A5 (Women) and Table A6 (Men)

Table A5.

Models of breast, lung, and colorectal cancer in women.

Unadjusted Age Adjusted Full Model
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Breast Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSW 0.88 (0.75–1.03) 0.98 (0.83–1.14) 0.90 (0.77–1.06)
p-value 0.11 0.76 0.19
Lung Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSW 1.14 (0.84–1.54) 1.83 (1.35–2.49) 1.20 (0.89–1.64)
p-value 0.42 0.00038 0.25
Colorectal Cancer
WSEM 1 (reference) 1 (reference) 1 (reference)
WSW 0.77 (0.56–1.06) 1.09 (0.79–1.51) 1.12 (0.81–1.56)
p-value 0.099 0.60 0.49

Table A6.

Models of prostate, lung, and colorectal cancer in men.

Unadjusted Age Adjusted Full Model
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Prostate Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSM 0.81 (0.71–0.93) 1.09 (0.95–1.24) 1.11 (0.97–1.26)
p-value 0.0013 0.22 0.14
Lung Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSM 1.04 (0.79–1.38) 1.41 (1.07–1.86) 0.93 (0.71–1.24)
p-value 0.76 0.022 0.63
Colorectal Cancer
MSEW 1 (reference) 1 (reference) 1 (reference)
MSM 0.79 (0.62–1.01) 1.01 (0.79–1.29) 1.01 (0.79–1.28)
p-value 0.048 0.93 0.97

Author Contributions

Conceptualisation, C.L.S. and G.L.; methodology, C.L.S. and S.U.; formal analysis, S.U.; writing—original draft preparation, S.U and C.L.S.; writing—review and editing, S.U., G.L., and C.L.S. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Ethical approval was not required for this analysis. This is detailed in the UK Biobank website: https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics (accessed on 1 March 2023) with the relevant section as follows: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval. This RTB approval was granted initially in 2011 and it is renewed on a 5-yearly cycle: UK Biobank successfully applied to renew it in 2016 and 2021.

Informed Consent Statement

UK Biobank obtained informed consent from all participants before recruitment. Details are given on the UK Biobank website: https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/Consent.pdf (accessed on 1 March 2023).

Data Availability Statement

This research was a secondary data analysis of data from UK Biobank, as specified in the Acknowledgements Section.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

No specific funding was obtained for this project. G.L. is supported by Cancer Research UK Advanced Clinician Scientist Fellowship C18081/A18180.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.McDermott E., Nelson R., Weeks H. The Politics of LGBT+ Health Inequality: Conclusions from a UK Scoping Review. Int. J. Environ. Res. Public Health. 2021;18:826. doi: 10.3390/ijerph18020826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Elliott M.N., Kanouse D.E., Burkhart Q., Abel G.A., Lyratzopoulos G., Beckett M.K., Schuster M.A., Roland M. Sexual Minorities in England Have Poorer Health and Worse Health Care Experiences: A National Survey. J. Gen. Intern. Med. 2015;30:9–16. doi: 10.1007/s11606-014-2905-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Institute of Medicine (US) Committee on Lesbian, Gay, Bisexual, and Transgender Health Issues and Research Gaps and Opportunities . The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. The National Academies Collection: Reports funded by National Institutes of Health; Washington, DC, USA: National Academies Press; Washington, DC, USA: 2011. [(accessed on 23 January 2023)]. Available online: http://www.ncbi.nlm.nih.gov/books/NBK64806/ [PubMed] [Google Scholar]
  • 4.Boehmer U., Dennert G., editors. LGBT Populations and Cancer in the Global Context. Springer International Publishing; Cham, Switzerland: 2022. [(accessed on 23 January 2023)]. Available online: https://link.springer.com/10.1007/978-3-031-06585-9. [Google Scholar]
  • 5.Dawson S., Campbell S.M., Giles S.J., Morris R.L., Cheraghi-Sohi S. Black and minority ethnic group involvement in health and social care research: A systematic review. Health Expect. 2018;21:3–22. doi: 10.1111/hex.12597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rayment J., Lanlehin R., McCourt C., Husain S.M. Involving seldom-heard groups in a PPI process to inform the design of a proposed trial on the use of probiotics to prevent preterm birth: A case study. Res. Involv. Engagem. 2017;3:11. doi: 10.1186/s40900-017-0061-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Crowe S., Barker E., Roberts M., Lloyd L., de Barros C.M., Ben Rebelo-Harris B., Meads C., Saunders C.L. Are we asking the right questions? Working with the LGBTQ+ community to prioritise healthcare research themes. Res. Involv. Engagem. 2021;7:64. doi: 10.1186/s40900-021-00298-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Saunders K., Setting Up My LGBTQ+ Research Prioritisation Project NIHR School for Primary Care Research Blog. 2021. [(accessed on 1 March 2022)]. Available online: https://www.spcr.nihr.ac.uk/news/blog/setting-up-my-lgbtq-research-prioritisation-project.
  • 9.de Barros C.M., Saunders K., Crowe S. LGBTQ+ Research and Involvement—What Have We Learnt? Primary Care Unit, University of Cambridge Blog. 2022. [(accessed on 1 March 2022)]. Available online: https://www.phpc.cam.ac.uk/pcu/lgbtq-research-and-involvement-what-have-we-learnt/
  • 10.Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., Boyle P. Tobacco smoking and cancer: A meta-analysis. Int. J. Cancer. 2008;122:155–164. doi: 10.1002/ijc.23033. [DOI] [PubMed] [Google Scholar]
  • 11.Burkhalter J.E. Smoking in the LGBT Community. In: Boehmer U., Elk R., editors. Cancer and the LGBT Community: Unique Perspectives from Risk to Survivorship. Springer International Publishing; Cham, Switzerland: 2015. pp. 63–80. [DOI] [Google Scholar]
  • 12.Gruskin E.P., Greenwood G.L., Matevia M., Pollack L.M., Bye L.L. Disparities in Smoking Between the Lesbian, Gay, and Bisexual Population and the General Population in California. Am. J. Public Health. 2007;97:1496–1502. doi: 10.2105/AJPH.2006.090258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Boehmer U., Miao X.P., Ozonoff A. Cancer Survivorship and Sexual Orientation. Cancer-Am. Cancer Soc. 2011;117:3796–3804. doi: 10.1002/cncr.25950. [DOI] [PubMed] [Google Scholar]
  • 14.Saunders C.L., MacCarthy S., Meads C., Massou E., Mant J., Saunders A.M., Elliott M.N. Long-term conditions among sexual minority adults in England: Evidence from a cross-sectional analysis of responses to the English General Practice Patient Survey. BJGP Open. 2021;5:BJGPO.2021.0067. doi: 10.3399/BJGPO.2021.0067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Frisch M., Smith E., Grulich A., Johansen C. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am. J. Epidemiol. 2003;157:966–972. doi: 10.1093/aje/kwg067. [DOI] [PubMed] [Google Scholar]
  • 16.Saunders C.L., Meads C., Abel G.A., Lyratzopoulos G. Associations Between Sexual Orientation and Overall and Site-Specific Diagnosis of Cancer: Evidence from Two National Patient Surveys in England. J. Clin. Oncol. 2017;35:3654–3661. doi: 10.1200/JCO.2017.72.5465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Blondeel K., Say L., Chou D., Toskin I., Khosla R., Scolaro E., Temmerman M. Evidence and knowledge gaps on the disease burden in sexual and gender minorities: A review of systematic reviews. Int. J. Equity Health. 2016;15:16. doi: 10.1186/s12939-016-0304-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Saunders C.L., Massou E., Waller J., Meads C., Marlow L., Usher-Smith J.A. Cervical screening attendance and cervical cancer risk among women who have sex with women. J. Med. Screen. 2021;28:349–356. doi: 10.1177/0969141320987271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fredriksen-Goldsen K.I., Simoni J.M., Kim H.J., Lehavot K., Walters K.L., Yang J., Hoy-Ellis C.P. The health equity promotion model: Reconceptualization of lesbian, gay, bisexual, and transgender (LGBT) health disparities. Am. J. Orthopsychiatry. 2014;84:653–663. doi: 10.1037/ort0000030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Meyer I.H. Prejudice, Social Stress, and Mental Health in Lesbian, Gay, and Bisexual Populations: Conceptual Issues and Research Evidence. Psychol. Bull. 2003;129:674–697. doi: 10.1037/0033-2909.129.5.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Poteat T.C., Adams M.A., Malone J., Geffen S., Greene N., Nodzenski M., Lockhart A.G., Su I., Dean L.T. Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States. Cancer. 2021;127:3514–3522. doi: 10.1002/cncr.33629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Huo D., A Adebamowo C., O Ogundiran T., E Akang E., Campbell O., Adenipekun A., Cummings S., Fackenthal J., Ademuyiwa F., Ahsan H., et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br. J. Cancer. 2008;98:992–996. doi: 10.1038/sj.bjc.6604275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hodson K., Meads C., Bewley S. Lesbian and bisexual women’s likelihood of becoming pregnant: A systematic review and meta-analysis. BJOG. 2017;124:393–402. doi: 10.1111/1471-0528.14449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Macmillan.or.uk LGBT People with Cancer: The Emerging Picture. 2022. [(accessed on 10 July 2022)]. Available online: https://www.macmillan.org.uk/_images/lgbt-people-with-cancer_tcm9-282785.pdf.
  • 25.Hulbert-Williams N.J., Plumpton C., Flowers P., McHugh R., Neal R., Semlyen J., Storey L. The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey. Eur. J. Cancer Care. 2017;26:e12670. doi: 10.1111/ecc.12670. [DOI] [PubMed] [Google Scholar]
  • 26.MacCarthy S., Saunders C.L., Elliott M.N. Increased Reporting of Sexual Minority Orientation from 2009 to 2017 in England and Implications for Measuring Sexual Minority Health Disparities. LGBT Health. 2020;7:393–400. doi: 10.1089/lgbt.2019.0181. [DOI] [PubMed] [Google Scholar]
  • 27.Griggs J., Maingi S., Blinder V., Denduluri N., Khorana A.A., Norton L., Francisco M., Wollins D.S., Rowland J.H. American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. J. Clin. Oncol. 2017;35:2203–2208. doi: 10.1200/JCO.2016.72.0441. [DOI] [PubMed] [Google Scholar]
  • 28.Quinn G.P., Sanchez J.A., Sutton S.K., Vadaparampil S.T., Nguyen G.T., Green B.L., Kanetsky P.A., Schabath M.B. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. CA Cancer J. Clin. 2015;65:384–400. doi: 10.3322/caac.21288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Margolies L., Brown C.G. Current state of knowledge about cancer in LGBT people. Semin. Oncol. Nurs. 2018;34:3–11. doi: 10.1016/j.soncn.2017.11.003. [DOI] [PubMed] [Google Scholar]
  • 30.Saunders C.L., Massou E. Using UK Biobank for sexual minority health research. J. Comp. Eff. Res. 2021;10:1001–1010. doi: 10.2217/cer-2021-0052. [DOI] [PubMed] [Google Scholar]
  • 31.Sudlow C., Gallacher J., Allen N., Beral V., Burton P., Danesh J., Downey P., Elliott P., Green J., Landray M., et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bycroft C., Freeman C., Petkova D., Band G., Elliott L.T., Sharp K., Motyer A., Vukcevic D., Delaneau O., O’Connell J., et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–209. doi: 10.1038/s41586-018-0579-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.UK Biobank Malignant Cancer Summary Report. [(accessed on 8 December 2022)]. Available online: https://biobank.ndph.ox.ac.uk/~bbdatan/CancerSummaryReport.html.
  • 34.Sexual Orientation QMI—Office for National Statistics. [(accessed on 23 January 2023)]; Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/sexuality/methodologies/sexualidentityukqmi.
  • 35.Data-Field 31. [(accessed on 28 July 2022)]. Available online: https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=31.
  • 36.Weir C.B., Jan A. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. [(accessed on 28 July 2022)]. BMI Classification Percentile And Cut Off Points. Available online: http://www.ncbi.nlm.nih.gov/books/NBK541070/ [PubMed] [Google Scholar]
  • 37.Cochran S.D., Bandiera F.C., Mays V.M. Sexual orientation-related differences in tobacco use and secondhand smoke exposure among US adults aged 20 to 59 years: 2003-2010 National Health and Nutrition Examination Surveys. Am. J. Public Health. 2013;103:1837–1844. doi: 10.2105/AJPH.2013.301423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cochran S.D., Mays V.M., Bowen D., Gage S., Bybee D., Roberts S.J., Goldstein R.S., Robison A., Rankow E.J., White J. Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am. J. Public Health. 2001;91:591–597. doi: 10.2105/ajph.91.4.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hagger-Johnson G., Taibjee R., Semlyen J., Fitchie I., Fish J., Meads C., Varney J. Sexual orientation identity in relation to smoking history and alcohol use at age 18/19: Cross-sectional associations from the Longitudinal Study of Young People in England (LSYPE) BMJ Open. 2013;3:e002810. doi: 10.1136/bmjopen-2013-002810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hatzenbuehler M.L., McLaughlin K.A., Slopen N. Sexual orientation disparities in cardiovascular biomarkers among young adults. Am. J. Prev. Med. 2013;44:612–621. doi: 10.1016/j.amepre.2013.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mercer C.H., Bailey J.V., Johnson A.M., Erens B., Wellings K., Fenton K.A., Copas A.J. Women who report having sex with women: British national probability data on prevalence, sexual behaviors, and health outcomes. Am. J. Public Health. 2007;97:1126–1133. doi: 10.2105/AJPH.2006.086439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.The Global Burden of Cancer Attributable to Risk Factors, 2010–2019: A Systematic Analysis for the Global Burden of Disease Study 2019—The Lancet. [(accessed on 2 February 2023)]. Available online: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01438-6/fulltext.
  • 43.Brown K.F., Rumgay H., Dunlop C., Ryan M., Quartly F., Cox A., Deas A., Elliss-Brookes L., Gavin A., Hounsome L., et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br. J. Cancer. 2018;118:1130–1141. doi: 10.1038/s41416-018-0029-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Meads C., Moore D. Breast cancer in lesbians and bisexual women: Systematic review of incidence, prevalence and risk studies. BMC Public Health. 2013;13:1127. doi: 10.1186/1471-2458-13-1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Rosser B.R.S., Hunt S.L., Capistrant B.D., Kohli N., Konety B.R., Mitteldorf D., Ross M.W., Talley K.M., West W. Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature. Curr. Sex Health Rep. 2019;11:430–441. doi: 10.1007/s11930-019-00234-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Berner A.M., Webster R., Hughes D.J., Tharmalingam H., Saunders D.J. Education to Improve Cancer Care for LGBTQ+ Patients in the UK. Clin. Oncol. 2021;33:270–273. doi: 10.1016/j.clon.2020.12.012. [DOI] [PubMed] [Google Scholar]
  • 47.Washington H.A. Burning Love: Big tobacco takes aim at LGBT youths. Am. J. Public Health. 2002;92:1086–1095. doi: 10.2105/AJPH.92.7.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Crowe S., Fenton M., Hall M., Cowan K., Chalmers I. Patients’, clinicians’ and the research communities’ priorities for treatment research: There is an important mismatch. Res. Involv. Engagem. 2015;1:2. doi: 10.1186/s40900-015-0003-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

This research was a secondary data analysis of data from UK Biobank, as specified in the Acknowledgements Section.


Articles from Cancers are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES